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Abstract
Background: Severe arrhythmias or heart failure may be surrogates of myocardial involvement in patients with
connective tissue disorders (CTD). However, most patients present with unspecific symptoms, normal ECG, and
preserved left ventricular ejection fraction (LV-EF). Therefore, timely diagnosis by an accurate technique is crucial.
Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has proven value for the detection
of focal processes, but due to the often diffuse character of fibrosis/inflammation in CTD patients, CMR mapping
techniques might be of incremental value for the assessment of myocardial involvement. Purpose of this study
was to evaluate a multi-parametric CMR protocol as a screening tool for myocardial involvement in CTD patients.
Methods: Forty CTD patients were prospectively enrolled and underwent CMR, twenty healthy volunteers served
as control group.
Results: Mean LV-EF was 62 %; LGE prevalence was low (18 %). CTD patients had higher native T1 (1008 vs. 962 ms,
p = 0.001), lower post contrast T1 (494 vs. 526 ms, p = 0.008), expanded extracellular volume (ECV) (28 vs. 25 %, p =
0.001), and higher T2 values (53 vs. 49 ms, p < 0.001) compared to controls. Among patients with values higher
than the 95 % percentile of healthy controls, native T1 and T2 values seem to be the most promising discriminators.
Conclusion: CTD patients showed higher T1, ECV, and T2 values compared to controls, with most significant
differences for native T1 and T2, which seem to be independent of the presence of LGE. Our data suggest that CMR
mapping techniques are of incremental value in the detection of myocardial involvement in CTD patients.
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Background
Connective tissue disorders (CTD) are a heterogeneous
form of rheumatic disorders comprising systemic lupus
erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s
syndrome, inflammatory muscle diseases and overlap
syndrome [1]. There is a high variety in the prevalence
of CTD, which may occur at all ages, but show a higher
prevalence in young adults [1]. SLE is one of the most
common autoimmune disorders in the western world
with a prevalence ranging from 15 to 50 per 100,000
persons [1]. Cardiovascular complications may manifest
as inflammation of valves, myocardium, pericardium
resulting in myocardial dysfunction, and heart failure
[2]. The prevalence of SSc is estimated about 26 per
100,000 persons [1]. SSc is characterized by structural
and functional abnormalities of small blood vessels,
fibrosis of the skin and internal organs, activation of the
immune system and autoimmunity [1]. Myocardial
involvement often remains subclinical, however autopsy
studies reveal diffuse myocardial fibrosis in up to 80 %
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of cases [3–6], and sudden cardiac death occurs in up to
21 % of SSc patients [5]. Therefore, timely detection of
myocardial involvement in stages, which might be po-
tentially reversible by an adequate treatment regimen, is
of high clinical interest in patients with CTD.
Cardiovascular magnetic resonance (CMR) offers beside
functional assessment excellent tissue characterization
without the need of radiation. Recent data suggest that a
CMR approach, including late gadolinium enhancement
(LGE) for the detection of focal fibrosis, and T1 mapping
sequences for the detection of diffuse fibrosis, might be
useful in the detection of myocardial involvement in pa-
tients with SLE and SSc [2, 3]. However, for the assess-
ment of inflammation, these groups used standard T2-
weighted images, which are known for severe limitations
(e.g. proneness for artifacts) [7]. In the meantime, new T2
mapping sequences were developed, overcoming most of
the standard T2-weighting limitations [8].
Consequently, aim of our study was to evaluate a com-
prehensive CMR protocol, including LGE and quantita-
tive T1 and T2 mapping techniques for the assessment
of both fibrosis and inflammation, as a screening tool




Forty patients presenting at our institution between
October 2013 and March 2016 were consecutively en-
rolled if they fulfilled the following criteria: 1) connective
tissue disorder; and 2) no history of CAD, myocardial
infarction and/or prior revascularization; and 3) success-
fully underwent CMR imaging. Exclusion criteria were
contraindications for CMR (e.g. pregnancy, pacemaker/
ICD, glomerular filtration rate <30 ml/min., previous
adverse reactions to gadolinium, cochlea implant).
Healthy volunteers (n = 20) with no history of cardiac
disease and free of symptoms served as control group.
Prior to CMR, all participants provided a blood sample
for measurement of hematocrit. The ethics committee of
the University of Tuebingen approved the study and all
patients gave written informed consent.
CMR protocol
ECG-gated CMR was performed in breath-hold using a
1.5 T Magnetom Aera (Siemens Healthcare, Erlangen,
Germany) in line with current recommendations [9].
Both cine and LGE short axis images were prescribed
every 10 mm (slice thickness 6 mm) from base to apex.
In-plane resolution was typically 1.2 × 1.8 mm. Cine was
performed using a steady-state free-precession (SSFP)
sequence. LGE images were acquired on average 5–
10 min after contrast using a segmented inversion
recovery gradient echo (IR-GRE)-sequence constantly
adjusting inversion time to null normal myocardium [10,
11]. The contrast dose (Gadopentetate-Dimeglumine)
was 0.15 mmol/kg.
A modified look-locker inversion recovery prototype
sequence (MOLLI) was used for T1 mapping and per-
formed in a single midventricular short-axis (SAX)
slice at mid-diastole, prior to and 20 min after ad-
ministration of contrast, in line with current recom-
mendations [12, 13].
Short axis T2 mapping was performed in a matching
midventricular SAX before administration of contrast
agent using an ECG-triggered T2-prepared single-shot
bSSFP prototype sequence with multiple T2 preparation
times [8].
More detailed information on T1 and T2 mapping
sequences is provided in the Additional file 1.
CMR analysis
Cine and LGE images were evaluated by experienced ob-
servers (S.G., H.M.) as described elsewhere [14]. In brief,
endocardial and epicardial borders were outlined on the
short-axis cine images. Volumes, mass and ejection-
fraction were derived by summation of epicardial and
endocardial contours. Extent of LGE was assessed using
QMass software (Medis, Leiden, The Netherlands), and
the results were expressed as percentage of myocardial
mass. The distribution of LGE was characterized as epi-
cardial, intramural, transmural, or subendocardial [14].
Color-coded T1, ECV, and T2 maps were generated
based on inline-generated, motion corrected raw images
using QMap software 1.0 (Medis, Leiden, the
Netherlands) in a single matching midventricular SAX.
Motion-corrected T1 maps were examined for quality in
three modalities: 1) raw T1 images 2) T1 maps 3) R2
maps. Endo- and epicardial contours were manually
drawn by two experienced observers (S.G., A.M.), and
then divided into 6 segments using the anterior right
ventricular insertion point as reference. Care was taken
to avoid partial volume effects at the endocardial and
epicardial borders for T1, ECV and T2 maps. Global T1,
ECV, and T2 values were calculated: T1 values were de-
termined by fitting an exponential model to the mea-
sured data [15]. Prior to CMR, the hematocrit was
determined in all subjects, allowing with native and post
contrast T1 measurements of the myocardium and
blood pool the calculation of extracellular volume
(ECV), using a previously described equation [16]. T2
results were obtained by fitting a 2-parameter intensity-
weighted exponential model (no offset term) [17].
Variables and definitions
All variables were collected directly from patients, and/
or medical records except CMR parameters, which were
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evaluated as described above. Most variables are self-
explanatory; all others are defined below.
Underlying connective tissue disorders had to fulfill
the diagnostic criteria of the American College of
Rheumatology or the European League Against Rheuma-
tism, respectively. Due to the variety of CTD (n = 5),
these were clustered into three subgroups:
1) SSc
2) SLE
3) “Others”: overlap syndrome, Sjögren’s syndrome, and
polymyositis.
Evaluation of disease activity in SSc and SLE patients:
SSc: ESSG = European scleroderma study group [18].
SLE: SLEDAI = Systemic Lupus Erythematosus Disease
Activity Index [19].
For SSc and SLE, subgroup analyses were performed.
Due to the low number of patients and the heterogeneity
of CTD in the “others” group (3 different CTD in 10 pa-
tients) no further subgroup analysis was performed.
Statistical analysis
Absolute numbers and percentages were computed to
describe the patient population. All continuous vari-
ables were tested for normality using the
Kolmogorov-Smirnov test. Normally distributed con-
tinuous variables were expressed as means (with
standard deviation) and skewed variables were pre-
sented as medians (with quartiles). Comparisons be-
tween groups were made using the Mann-Whitney U
test or the Fisher’s exact test, as appropriate. P-values
(two-tailed) of <0.05 were considered significant. All
statistical analyses were performed using SPSS, ver-
sion 22.0 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
In total n = 60 subjects were included in the final ana-
lysis, see Table 1: n = 40 patients with CTD, n = 20
healthy individuals served as control group. At inclusion,
CTD patients were 54 ± 17 years of age, predominantly
female (87 %), and did not differ significantly from the
control group, p = 0.10 for age and p = 0.27 for gender,
respectively.
Most patients suffered from SSc (n = 17) or SLE (n =
13). Others (n = 10) had overlap syndrome (n = 6), Sjög-
ren’s syndrome (n = 3), and polymyositis (n = 1). Nonspe-
cific dyspnea and angina were the most frequently
reported symptoms in the overall patient population (33
and 23 %, respectively). ECG abnormalities were
detected in n = 8 (20 %) of the patients. In detail, n = 3
showed left bundle branch block (in all of them CAD
could be excluded by coronary angiography), n = 2 had
atrial fibrillation (one patient had coronary angiography
and showed no CAD), n = 2 had ventricular extrasystoles
(in one of the patients CAD was ruled out by coronary
angiography), n = 1 patient showed a right bundle
branch block. The majority (60 %) of our overall CTD
population was on steroids during the time of CMR. De-
tails are displayed in Table 1.
General CMR results
CMR findings can be viewed in Table 2. The mean LV-
EF was 62 %, and did not differ to our control group (p
= 0.41). Furthermore, functional CMR parameters (LV
size, mass, etc.) were not significantly different between
CTD patients and controls. LGE was present in 7 (18 %)
of the CTD patients, most commonly occurring in a
non-ischemic pattern (epicardial and/or intramural)
[14]. LGE was not present in any of the controls.
Looking at the SSc and SLE subgroups (Tables 3
and 4) revealed that mean LV-EF was also preserved,
and the prevalence of LGE tended to be low (12 %
SSc, 23 % in SLE).
T1 and ECV results
We found higher native T1 values in the CTD patient
population: 1008 (990–1042) ms vs. 962 (947–987) ms
in controls, p = 0.001; Table 2, Fig. 1a. Post contrast T1
values were decreased in comparison to controls: 494
(477–522) ms vs. 526 (508–553) ms, p = 0.008, Table 2,
Fig. 1b. For T1-derived ECV measures, CTD patients
demonstrated significantly higher values: 28 (26–31) %
vs. 25 (24–27) % in the control group, p = 0.001, Table 2,
Fig. 1c. LGE-positive CTD patients had no significant
differences in their native, post T1 values, and ECV
results as compared to LGE-negative CTD patients (p =
0.36, p = 0.63, p = 0.76, respectively).
Subgroup analysis of the SSc and SLE patients revealed
higher T1 native and ECV values in SSc patients (1031
(1007–1075) ms, and 31 (28–34) %, respectively),
compared to 1002 (976–1015) ms and 26 (25–29) % in
SLE patients, both p < 0.01, also see Tables 3 and 4.
Furthermore, post contrast T1 values were lower in SSc
patients: 494 (474–525) vs. SLE patients: 507 (479–539).
However, this difference was not statistically significant
(p = 0.43). Compared to healthy controls, patients with
SSc demonstrated: 1) significantly higher median native
T1 values and ECV values (both p < 0.001), 2) signifi-
cantly decreased post contrast values (p = 0.02). Patients
with SLE showed increased median T1 native values in
comparison to healthy controls (p = 0.03). However, al-
though increased, ECV values did not differ significantly
to controls (p = 0.24). Furthermore, SLE patients demon-
strated lower post contrast values than controls without
reaching significance (p = 0.16). Figure 2 displays a LGE-
Mayr et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:67 Page 3 of 13
Table 1 Baseline characteristics
All patients SLEa SSca Other CTD
n = 40 n = 13 n = 17 n = 10
Age (yrs) 54 ± 17 45 ± 16 55 ± 16 62 ± 16
Gender (male) 5 (13 %) 3 (23 %) 1 (6 %) 1 (10 %)
Diagnosis
Systemic lupus erythematosus 13 (33 %) 13 (100 %) - -
Systemic sclerosis 17 (38 %) - 17 (100 %) -
Overlap syndrome 6 (15 %) - - 6 (60 %)
Sjögren’s syndrome 3 (7 %) - - 3 (30 %)
Polymyositis 1 (2 %) - - 1 (10 %)
Cardiovascular risk factors
Diabetes 1 (2 %) - - 1 (10 %)
Hypertension 13 (33 %) 4 (33 %) 4 (23 %) 5 (50 %)
Smokingb 14 (35 %) 6 (46 %) 7 (41 %) 1 (10 %)
Hyperlipidemia 7 (18 %) 1 (8 %) 2 (12 %) 4 (40 %)
Family history of CVD 14 (35 %) 6 (46 %) 4 (23 %) 4 (40 %)
Obesity (BMI≥ 30 kg/m2) 4 (10 %) 2 (15 %) 2 (12 %) -
Symptoms (multiple possible)
Angina 9 (23 %) 3 (23 %) 2 (12 %) 4 (40 %)
Dyspnea 13 (33 %) 3 (23 %) 6 (35 %) 4 (40 %)
Palpitations 3 (7 %) 1 (8 %) - 2 (20 %)
Syncope 1 (2 %) - - 1 (10 %)
ECG abnormality 8 (20 %) 1 (8 %) 3 (18 %) 4 (40 %)
Years since diagnosis
< 1 8 (20 %) 5 (38.5 %) 1 (6 %) 2 (20 %)
1–4 12 (30 %) 2 (15 %) 9 (53 %) 1 (10 %)
5–9 6 (15 %) 1 (8 %) 3 (18 %) 2 (20 %)
≥ 10 14 (35 %) 5 (38.5 %) 4 (23 %) 5 (50 %)
Disease activity
SLEDAI - 16 (6–23) - -
ESSG - - 3.5 (1.4–5.5) -
Hematocrit 0.38 (0.34–0.40) 0.38 (0.34–0.40) 0.38 (0.34–0.42) 0.38 (0.37–0.39)
Medication
Beta-blockers 6 (15 %) 4 (31 %) - 2 (20 %)
ARB 19 (48 %) 5 (39 %) 9 (53 %) 5 (50 %)
ASA 6 (15 %) 1 (8 %) 2 (12 %) 3 (30 %)
CCB 6 (15 %) 1 (8 %) 4 (23 %) 1 (10 %)
Statins 7 (18 %) 3 (23 %) 2 (12 %) 2 (20 %)
Diuretics 6 (15 %) 3 (23 %) 2 (12 %) 1 (10 %)
Steroids 24 (60 %) 10 (77 %) 8 (47 %) 6 (60 %)
NSAID 1 (2 %) 1 (8 %) - -
Chloroquines 4 (10 %) 2 (15 %) 1 (6 %) 1 (10 %)
Antibodies 1 (2 %) 1 (8 %) - -
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negative female SLE patient showing increased native
T1, ECV and T2, and decreased post contrast T1 values.
In our patients with ECG abnormalities, native and
post T1 values, and ECV were not significantly different
to the values in patients with normal ECG (p = 0.73, p =
0.65, p = 0.93, respectively).
T2 results
Median myocardial T2 values were significantly higher
in patients with CTD than in controls: 53 (52–58) ms
vs. 49 (48–51) ms, p < 0.001, Table 2, Fig. 1d. This differ-
ence remained significant independent of the patients’
LGE status; LGE-negative patients: 54 (51–58) ms, p ≤
0.001, and LGE-positive patients: 52 (52–58) ms, p =
0.001.
In the subgroup analysis, SSc patients had higher T2
values than patients with SLE: 58 (54–59) ms vs. 51 (49–
53) ms, p = 0.001. However, both (SSc and SLE) differed
significantly to the control group, p < 0.001, p = 0.02,
respectively, Tables 3 and 4.
These findings are illustrated by Fig. 3, displaying a
LGE negative SSc patient with severely increased values
for native T1, ECV and T2, and decreased values for
post contrast T1 in comparison to controls.
T2 values in patients with ECG abnormalities were not
significantly different from T2 values in patients with
normal ECG, p = 0.60.
Table 1 Baseline characteristics (Continued)
Cyclophosphamide 9 (23 %) 5 (39 %) 3 (18 %) 1 (10 %)
Azathioprine 3 (8 %) 2 (15 %) - 1 (10 %)
Methotrexate 1 (2 %) - - 1 (10 %)
All values are n (%) or mean ± SD or interquartile ranges
SLE systemic lupus erythematosus, SSc systemic sclerosis, CTD connective tissue disease, CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram,
SLEDAI systemic lupus erythematosus disease activity index, ACR American College of Rheumatology, ESSG European scleroderma study group, ARB angiotensin
receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug
apercentages based on number of SLE patients/SSc patients, respectively
bCurrent or ever-smokers
Table 2 CMR findings
Controls (n = 20) Patients (n = 40) P
LV-EF (%) 66 ± 4 62 ± 12 0.41
LV-EDV (ml) 109 ± 28 108 ± 36 0.76
LV-ESV (ml) 37 ± 13 41 ± 25 0.86
LV-SV 71 ± 16 66 ± 13 0.41
LV-EDD 45 ± 5 46 ± 5 0.67
LA (cm2) 20 ± 4 20 ± 5 0.68
IVS (mm) 10 ± 2 9 ± 3 0.63
PA (mm) 24 ± 4 24 ± 6 0.56
LV mass (g) 76 ± 18 82 ± 24 0.50
LGE per patient - 7 (18 %)
Epicardial - 1 (2 %)
Intramural - 6 (15 %)
Transmural - 1 (2 %)
Subendocardial - -
% LV mass - 5.3
Native T1 (ms) 962 (947–987) 1008 (990–1042) 0.001
Post contrast T1 (ms) 526 (508–553) 494 (477–522) 0.008
ECV (%) 25 (24–27) 28 (26–31) 0.001
T2 (ms) 49 (48–51) 53 (52–58) <0.001
All values are n or mean ± SD or interquartile ranges
CMR cardiac magnetic resonance, LV left ventricular, EF ejection fraction, EDV
end-diastolic volume, ESV end-systolic volume, SV stroke volume, EDD end-
diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary
artery, LGE late gadolinium enhancement, ECV extracellular volume
Table 3 CMR findings systemic sclerosis (SSc)
Controls (n = 20) Patients (n = 17) P
LV-EF (%) 66 ± 4 62 ± 16 0.48
LV-EDV (ml) 109 ± 28 105 ± 29 0.82
LV-ESV (ml) 37 ± 13 38 ± 14 0.87
LV-SV 71 ± 16 67 ± 16 0.63
LV-EDD 45 ± 5 46 ± 4 0.42
LA (cm2) 20 ± 4 20 ± 5 0.93
IVS (mm) 10 ± 2 10 ± 4 0.76
PA (mm) 24 ± 4 26 ± 8 0.81
LV mass (g) 76 ± 18 81 ± 31 0.82
LGE per patient - 2 (12 %)
Epicardial - -
Intramural - 2 (12 %)
Transmural - -
Subendocardial - -
% LV mass - 1.3
Native T1 (ms) 962 (947–987) 1031 (1007–1075) <0.001
Post contrast T1 (ms) 526 (508–553) 494 (474–525) 0.02
ECV (%) 25 (24–27) 31 (28–34) <0.001
T2 (ms) 49 (48–51) 58 (54–59) <0.001
All values are n or mean ± SD or interquartile ranges
CMR cardiac magnetic resonance, LV left ventricular, EF ejection fraction, EDV
end-diastolic volume, ESV end-systolic volume, SV stroke volume, EDD end-
diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary
artery, LGE late gadolinium enhancement, ECV extracellular volume
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Values above the 95 % percentile of normal
Defining the 95 % percentile of our control group as a
threshold for definite abnormal values, we found values
above 1033 ms for native T1, below 451 ms for post con-
trast T1, above 32 % for ECV, and above 54 ms for T2
to be abnormal, see Fig. 4.
25 % (n = 10) of the CTD patients demonstrated a na-
tive T1 value above the 95 % percentile of the matched
control group: n = 9 patients were LGE-negative, n = 1
patient was LGE- positive, also see Fig. 4a. In n = 3
patients, post contrast values were below 455 ms, all of
them were reported LGE-negative, see Fig. 4b. Measure-
ment of ECV revealed that n = 8 patients had definite
abnormal values (n = 7 LGE-negative, n = 1 LGE-
positive), see Fig. 4c. Almost 40 % (15 out of 40 CTD
patients) showed definite abnormal T2 values: n = 13
LGE-negative, n = 2 LGE-positive, see Fig. 4d.
Almost 50 % of SSc patients (8 out of 17 SSc) had an
increased native T1 value above the 95 % percentile of
controls, and only one of these was LGE-positive. Three
patients (all LGE-negative) had post contrast T1 values
lower, and six patients (5 LGE-negative, 1 LGE-positive)
had ECV values higher than the 95 % percentile of con-
trols. 65 % of the SSc patients demonstrated definitely
abnormal T2 values: n = 10 were LGE-negative, n = 1
LGE-positive, also see Fig. 5.
In the SLE subgroup, values higher than the 95 % per-
centile of controls were found in n = 3 patients (23 %),
with one patient showing both increased T2 and native
T1 values beyond the 95 % percentile of normal, and the
two other patients isolated increased ECV or T2 beyond
the 95 % percentile of normal, respectively. Only one of
these patients was reported LGE-positive, also see Fig. 5.
Discussion
To the best of our knowledge, this is the first study
evaluating cardiac involvement in patients with CTD
and preserved left ventricular ejection fraction by a com-
prehensive CMR approach, including LGE CMR, as well
as T1 and T2 mapping techniques. The findings are as
follows: 1) Patients with CTD show increased native T1,
ECV, T2 and decreased post contrast T1 values com-
pared to controls. 2) Subgroup analysis of SSc and SLE
patients revealed that native T1 and T2 values seem to
be higher in patients with SSc compared to patients with
SLE. However, both parameters can separate between
SSc/SLE patients and controls. 3) Abnormal values be-
yond the 95 % percentile of healthy controls might help
to detect myocardial involvement in patients with CTD
even in the absence of LGE.
Patient characteristics and general CMR results
Most patients were middle-aged and female, in line with
previous reports [3]. The majority of patients was non-
or oligosymptomatic, and had normal ECG, underlining
that the diagnosis of cardiac involvement is a challenge
in CTD, Table 1. The mean LV-EF in our cohort was
preserved (62 %), cardiac dimensions did not differ from
controls, Table 2. LGE was present in 18 % of the CTD
patients, occurring in a non-ischemic pattern in accord-
ance with other studies [2, 3, 20–22].
T1 and ECV results
We found higher native T1 values and increased ECV in
our CTD population in comparison to controls, Table 2,
Fig. 1a + c. Furthermore, post contrast T1 values were
decreased in comparison to controls, Table 2, and Fig. 1b.
Since these differences are independent of the presence
of LGE, they may allow early detection of subclinical
myocardial alterations in patients with CTD, as reported
in other inflammatory cardiomyopathies [23, 24].
In the SSc subgroup, differences for native T1 and
ECV were even larger than in the overall CTD popula-
tion, suggesting a high rate of diffuse myocardial in-
volvement detected by T1 mapping, supporting data
from Ntusi et al. [3], who found also elevated native T1
and ECV in SSc patients. At first sight, the mapping data
in this study seem to conflict with the low prevalence of
Table 4 CMR findings systemic lupus erythematosus (SLE)
Controls (n = 20) Patients (n = 13) P
LV-EF (%) 66 ± 4 63 ± 7 0.60
LV-EDV (ml) 109 ± 28 111 ± 36 1
LV-ESV (ml) 37 ± 13 43 ± 24 0.82
LV-SV 71 ± 16 67 ± 12 0.55
LV-EDD 45 ± 5 46 ± 4 1
LA (cm2) 20 ± 4 17 ± 3 0.02
IVS (mm) 10 ± 2 9 ± 1 0.35
PA (mm) 24 ± 4 22 ± 3 0.08
LV mass (g) 76 ± 18 85 ± 21 0.41
LGE per patient - 3 (23 %)
Epicardial - 1 (8 %)
Intramural - 2 (15 %)
Transmural - 1 (8 %)
Subendocardial - -
% LV mass - 6.2
Native T1 (ms) 962 (947–987) 1002 (976–1015) 0.03
Post contrast T1 (ms) 526 (508–553) 507 (479–539) 0.16
ECV (%) 25 (24–27) 26 (25–29) 0.24
T2 (ms) 49 (48–51) 51 (49–53) 0.02
All values are n or mean ± SD or interquartile ranges
CMR cardiac magnetic resonance, LV left ventricular, EF ejection fraction, EDV
end-diastolic volume, ESV end-systolic volume, SV stroke volume, EDD end-
diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary
artery, LGE late gadolinium enhancement, ECV extracellular volume
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LGE (12 %). However, LGE has its strengths in detecting
focal processes (e.g. infarcted myocardium vs. remote
myocardium), whereas in diffuse processes this tech-
nique is of limited value. Conversely, mapping tech-
niques, which provide absolute quantitative values,
rather than just visual or semi-quantitative interpretation
of the images, perform well in the assessment of diffuse
myocardial processes [7]. Therefore, the T1 and ECV
findings in this study might be the surrogate for the high
rate of diffuse fibrosis (44–100 %) observed by endo-
myocardial biopsy or autopsy in SSc patients [25, 26],
and might be a useful tool not only for detection of
myocardial involvement, but also for evaluation of an
adequate response to immunosuppressive agents during
the clinical course of the disease.
In the SLE subgroup, we observed lower T1 and ECV
differences to controls than in the SSc subgroup. Conse-
quently, although showing increased ECV and decreased
post contrast T1 values compared to controls, the differ-
ence was significant only for native T1 values, p = 0.03.
This might have at least two reasons: 1) In contrast
to SLE patients, autopsy studies from SSc patients re-
vealed a high rate of diffuse fibrosis, which might be
the surrogate for higher native T1 and ECV values in
SSc patients [25, 26]. 2) Our finding that native T1
seems to separate best between SLE patients and
healthy controls, is supported by a recent study [2],
which identified native T1 a) as the best parameter to
separate between SLE patients and controls, and b) as
an independent predictor of the underlying SLE diag-
nosis. However, in the study by Puntmann [2] also
post contrast T1 values and ECV differed significantly
to the control group. They included 33 asymptomatic
SLE patients, with an activity index (SLEDAI) of 0,
and observed a high LGE prevalence of 61 % (n = 20),
which is in contrast to our study (SLEDAI 16, preva-
lence of LGE 23 %). Another explanation for these
differences might be the time duration from SLE diag-
nosis to CMR imaging: In the study from Puntmann et al.,
the average time from SLE diagnosis to imaging was
Fig. 1 Box plots for median native T1 (a), post contrast T1 (b), extracellular volume fraction (ECV; c), and T2 mapping (d) in controls, all CTD
patients, late gadolinium enhancement (LGE) negative CTD patients, and LGE positive CTD patients; the center line in each box represents the
median, whereas the lower and upper limits of each box represent the 25th and 75th percentiles, respectively. CTD patients (all, LGE negative,
LGE positive except for native T1 and post contrast T1, respectively) showed values which were significantly different to the values of the control
group; */**/*** each p ≤ 0.05)
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7.4 years whereas in our study almost 40 % had their
CMR within the first year of SLE diagnosis. Therefore, it
might be argued that the grade of diffuse fibrosis, as well
as the presence of focal fibrosis detected by LGE, might
increase in later stages of the disease. Since both studies
found that native T1 is the most sensitive parameter to
separate between SLE patients and controls, native T1
may play an important role in: a) initial diagnosis of
myocardial involvement and b) the monitoring in SLE
patients.
Our findings add knowledge to the potential role of
T1 mapping in patients with different CTD, since this
technique seems to provide more detailed tissue
characterization than LGE alone. This might have clin-
ical implications for the assessment of disease activity,
and monitoring of the response to immunosuppressive
medication in CTD patients. Moreover, since T1 and
ECV values in patients with ECG abnormalities did not
differ to the values of patients with normal ECG, the
presence of ECG abnormalities alone may be of limited
diagnostic value for detecting myocardial involvement in
CTD patients.
T2 results
In contrast to T1 mapping, myocardial T2 values correl-
ate closely with free tissue water content [27, 28], predis-
posing them for the assessment of active myocardial
inflammation in systemic disorders such as CTD. Newer
T2 mapping sequences provide objective and robust data
[8, 29], and will most likely replace previously described
T2-weighted sequences [7].
As expected in systemic inflammatory disorders such
as CTD, median myocardial T2 values were significantly
higher than in controls, suggesting myocardial involve-
ment due to systemic inflammation, Table 2, Fig. 1d. Of
note, T2 performs even better than native T1 to separate
controls from CTD patients (p < 0.001, p = 0.001,
respectively). This difference remains significant by
dividing the CTD population in a LGE-positive and a
LGE-negative group, underlining the additional value of
T2 mapping in comparison to the performance of LGE
CMR alone.
For the SSc subgroup, we found only studies in the lit-
erature that used T2-weighted images for the assessment







Fig. 2 Patient with SLE. Cardiovascular magnetic resonance (CMR) of a 30-year old female presenting with no symptoms and normal ECG for her
sixth cycle of cyclophosphamide. 3 months ago, the diagnosis SLE was settled. Cine images (a) revealed a preserved LV-EF (63 %), LGE images (b)
demonstrated no enhancement. Native T1 map (c) showed an increased T1 with 999 ms (normal median range 962 (947–987) ms), decreased
post-contrast T1 (d) with 489 ms (normal median range 526 (508–553) ms), and expanded ECV (e) of 27 % (normal median range 25 (24–27) %).
T2 (f) was prolonged with 51 ms (normal median range 49 (48–51) ms)
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[3, 30]. We filled this gap and found higher T2 values both
than controls (p < 0.001), and patients with SLE (p =
0.001), suggesting a high grade of myocardial inflamma-
tion, possibly representing active disease, in SSc patients.
The occurrence of both myocardial inflammation and
diffuse fibrosis is a well-known finding in these patients
[3]. Thus, a comprehensive CMR approach including
LGE, T1 and T2 mapping seems a reasonable approach to
evaluate both chronic and active stages of the disease in
SSc patients.
Our data are also supported by a recent study [31],
which reported elevated T2 values in SLE patients
compared to controls. However, their T2 values were
higher in SLE patients and controls as compared to the
values in this study, which might have the following
reasons: 1) Different patient populations: our patients
were younger; 2) different grades of inflammation due to
different immunosuppressive treatment regimen: 77 % of
our patients were on steroids vs. only 17 % in the latter
study. 3) Differences in the T2 mapping sequence and
map analysis software. Therefore, as long as there are no
consistent mapping sequences, each institution should
create its individualized normal values [12]. Of note, T2
values of our control group were in line with the results
of other groups [32].
Since increased T2 values are supposed to represent
potentially reversible processes [31], T2 mapping might
play an important role as a quantitative biomarker,
which might serve as surrogate for response or failure of
immunosuppressive agents.
As shown above for T1 values, T2 values in patients
with normal vs. abnormal ECG did not differ signifi-
cantly, underlining the need for further detailed tissue
characterization for the detection of myocardial involve-
ment in CTD.
Values above the 95 % percentile of normal
Despite highly significant differences in T1 and T2
values between the CTD population and controls, there
is still some overlap in values, hampering the diagnosis
of myocardial involvement in the individual CTD







Fig. 3 CMR of a 45-year old female with a history of SSc since 15 years. She was suffering from nonspecific dyspnea, and palpitations. ECG was
unremarkable. Cine CMR (a) revealed a preserved LV-EF (61 %) with normal cardiac dimensions. LGE images (b) revealed no LGE. However, native
T1 (c) with 1108 ms, ECV (e) with 40 %, and T2 (f) with 61 ms were severely increased, whereas post contrast T1 (540 ms) (d) was within normal
range compared to our control group (median native T1 962 ms, ECV 25 %, post contrast T1 526 ms, T2 49 ms)
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percentile of our control group as a threshold for defin-
ite abnormal values in patients with CTD.
The majority of abnormal values were reported for T2
(n = 15), and native T1 (n = 10), suggesting to be the
most promising parameters for potential detection of
myocardial involvement. Of note, 87 % of these patients
with elevated T2 values, and 90 % of the patients with
elevated T1 native values, were LGE-negative, see Fig. 4.
In the SSc and SLE subgroups we found comparable
results, with native T1 and T2 as most frequent parame-
ters above the 95 % percentile of normal, and a high rate
of LGE-negative patients, see Fig. 5. These findings
underline the additional benefit of the newer mapping
techniques compared to LGE imaging alone.
Clinical implications
In this study, we could demonstrate that mapping
sequences in addition to LGE-CMR might be useful for
the detection of myocardial involvement in patients with
CTD. Patients with CTD show higher T1, ECV, and T2
values compared to healthy controls. These findings are
independent of the presence of LGE. Furthermore, sub-
group analysis in SSc and SLE patients revealed that native
T1 mapping and T2 mapping are the best parameters to
separate between normal subjects and patients. This could
be confirmed among patients with values higher than the
95 % percentile of controls, suggesting a combination of
both fibrosis and inflammation in CTD patients.
Despite potential life-threatening complications by
myocardial involvement of CTD, many patients will
present with nonspecific symptoms, normal ECG, and
preserved LV-EF. Thus, a comprehensive CMR approach
may be of future clinical importance not only for detec-
tion of myocardial involvement but also for response to
treatment. Nevertheless, larger randomized trials are
warranted to investigate the diagnostic and prognostic
value of abnormal mapping findings, before these se-





Fig. 4 Values above the 95 % percentile of normal. Values for T1 (native (a), post contrast (b)), ECV (c) and T2 (d) in controls, LGE negative and
LGE positive CTD patients indicating values beyond the 95th percentile (dotted line) of the control group, representing the threshold for definite
abnormal values (1033 ms for native T1, 451 ms for post contrast T1, 32 for ECV, and 54 ms for T2). Interestingly, in LGE negative patients most
frequent abnormal values were reported for native T1 (above 1033 ms), and for T2 (above 54 ms), suspicious of myocardial involvement. * = Some of
the values might be similar, with dots overlapping one another
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Limitations
Several potential limitations need to be addressed. Due
to the single center setting, potential center-specific bias
cannot be excluded. However, since most mapping se-
quences are vendor and center specific, there is still a
lack of established normal values and thresholds, so
preferably centers should establish their own normal
values and thresholds upon healthy controls, as sug-
gested by current recommendations [12].
The overall CTD group, and in particular the SSc and
SLE subgroups are small, but comparable in size to most
of the studies in the current literature dealing with CTD.
Furthermore, despite the relatively small numbers of pa-
tients, significant differences in the mapping parameters
were measured compared to controls.
Measuring global myocardial T1 or T2 values in a single
mid-ventricular slice might overlook focal processes. How-
ever, this approach is common practice [33, 34], less sub-
jective and might be even better comparable to follow-up
exams. Moreover, for comparing different CMR techniques
(native T1, post contrast T1, ECV, T2), it is fundamental
that measurements are made in matching locations.
Endomyocardial biopsy was not routinely performed.
However, it is well known that EMB has several limita-
tions, e.g. invasiveness, sampling error, lowering its diag-
nostic benefit. Furthermore, in oligosymptomatic
patients with preserved LV-EF, this would be a rather
unethical approach, and not in line with current guide-
lines [35].
Comparing mapping results to cardiac biomarkers
would have been of interest, however this was not
intention of our study, and should be investigated by
further studies.
Conclusions
We found increased values for native T1, ECV, T2, and
decreased values for post contrast T1 in our CTD popu-
lation with preserved LV-EF compared to controls, inde-
pendent of the presence of LGE. Native T1, and T2 as
the best discriminators to controls seem to have incre-
mental value in the detection of myocardial involvement
compared to LGE CMR alone, with the largest differ-
ences observed in patients with SSc. A potential benefit





Fig. 5 Subgroup analysis for patients with SSc and SLE. Values for native T1 (a), post contrast T1 (b), ECV (c) and T2 (d) in controls, LGE negative
and LGE positive SSc/SLE patients, indicating values beyond the 95th percentile (dotted line) of the control group, representing the threshold for
definite abnormal values (1033 ms for native T1, 451 ms for post contrast T1, 32 for ECV, and 54 ms for T2). * = Some of the values might be
similar, with dots overlapping one another
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diagnosis of myocardial involvement in a still dynamic
stage, yielding adequate treatment regimen, before
irreversible scar (LGE) will manifest. Beside diagnosis,
the new mapping techniques might be of value for
monitoring of the disease.
However, further studies are mandatory, before the
newer mapping sequences might be implemented in the
daily clinical routine for decision-making in patients
with CTD.
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